Released Mar 23, 2026, after the close
10-K filed Mar 23, 2026, 82 days after period end · 0001193125-26-119873
Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$11.65M$11.65M derived−21.4% vs Q4 2024+20.2% vs Q3 2025
Net Income-$46.76M-$46.76M derivedN/M vs Q4 2024N/M vs Q3 2025
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$38,049,000N/M
Operating Cash Flowderived-$26,435,000N/M
Margins · derived
Operating margin-326.7%+114.0 pt vs Q4 2024
Net margin-401.5%+87.7 pt vs Q4 2024
What the release said
The release
Same quarter
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|---|---|
| Revenue | $11.65M | $14.81M | $113.72M | $8.63M |
| Net Income | -$46.76M | -$72.44M | $31.07M | -$34.59M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR